Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) will present one oral and two poster presentations at the AD/PD conference in Copenhagen, March 17–21, 2026. Presentations cover enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker responses (NULISA-Seq-TM), and novel AβO-targeting antibodies.
The oral talk on March 21 details fusion of sabirnetug with an anti-transferrin receptor fragment; posters on March 17–18 cover biomarker analytics and antibody characterization. The oral data arise from an ongoing collaboration with JCR Pharmaceuticals using J-Brain Cargo® technology and support analytic plans for Phase 2 ALTITUDE‑AD.
Positive
- None.
Negative
- None.
News Market Reaction – ABOS
On the day this news was published, ABOS gained 0.30%, reflecting a mild positive market reaction. Argus tracked a peak move of +5.0% during that session. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $573K to the company's valuation, bringing the market cap to $191M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ABOS gained 5.1% while peers were mixed: IMUX up 6.42%, OVID up 5.73%, XBIT up 4.98%, but CRVO and ATRA declined. Momentum scanner showed IMUX modestly higher and QNCX lower, indicating a stock-specific reaction rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Clinical data update | Positive | -7.9% | CTAD data on EBD™ with 15–68 fold brain penetration and trial recruitment. |
| Nov 17 | Clinical trial milestone | Positive | -8.7% | First participant dosed in Phase 2 open-label extension of sabirnetug. |
| Nov 12 | Earnings and pipeline | Positive | -1.0% | Q3 2025 results with <b>$136.1M</b> cash and guidance into early 2027. |
| Nov 10 | Leadership change | Positive | +0.5% | Appointment of George Golumbeski, Ph.D., as Chairman of the Board. |
| Nov 05 | Earnings announcement date | Neutral | -6.4% | Scheduled date and webcast details for Q3 2025 results release. |
Several prior positive clinical and corporate updates were followed by negative 24h price reactions, suggesting a recent pattern of selling into good news.
Over the past few months, Acumen has focused on sabirnetug and its Enhanced Brain Delivery™ program. At CTAD in Dec 2025, it reported 15–68 fold increases in brain penetration in mice and detailed ALTITUDE-AD recruitment metrics (2,362 screened, 542 enrolled). It started a Phase 2 open-label extension in Nov 2025 and reported Q3 2025 financials showing cash supporting operations into early 2027. The current AD/PD 2026 presentations extend this trajectory with additional EBD™, biomarker, and antibody data.
Market Pulse Summary
This announcement highlights Acumen’s ongoing work to refine sabirnetug delivery and monitoring, including EBD™ research, biomarker analyses, and new AβO‑targeting antibodies being presented at AD/PD 2026. It builds on prior disclosures about Phase 2 ALTITUDE‑AD and Enhanced Brain Delivery efforts. Investors may focus on how these preclinical and biomarker insights inform future ALTITUDE‑AD readouts, the evolution of the JCR collaboration, and upcoming milestones tied to Phase 2 data and expanded analytical frameworks for CNS biomarkers.
Key Terms
amyloid beta oligomers medical
biomarker medical
transferrin receptor medical
immunotherapy medical
central nervous system medical
AI-generated analysis. Not financial advice.
NEWTON, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), announced today one oral and two poster presentations at the International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD) taking place in Copenhagen. The presentations will highlight new data regarding enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker treatment responses, and the development of new AβO-targeting antibodies. The conference will be held in-person and online March 17-21, 2026.
“The data we’re presenting reflects our dedication to finding better solutions for Alzheimer’s patients and their families,” said Jim Doherty, President and Chief Development Officer of Acumen. “By exploring enhanced brain delivery methods and developing more selective antibodies, we’re working toward treatments that could potentially improve effectiveness and safety, while expanding convenience and supporting a wider range of people impacted by Alzheimer’s disease.”
Acumen’s presentation details are as follows:
Oral Presentation
Title: Enhanced Brain Delivery of Sabirnetug After Fusion with an Anti-Transferrin Receptor Antibody Fragment in a Mouse Model of Alzheimer’s Disease
Date/Time: Saturday, March 21 at 8:40 – 10:40 a.m. CET
Session Name: 5940 - RESTORING NEURAL RESILIENCE IN ALS AND ALZHEIMER’S DISEASE (ID 21)
Presenting Author: Paul Shughrue, PhD, Vice President of Research and Portfolio Lead, Acumen Pharmaceuticals
Poster Presentations
Title: Sabirnetug Biomarker Treatment Responses: Exploratory Evaluation of the CNS Disease Panel NULISA-Seq-TM
Date/Time: Tuesday and Wednesday, March 17-18
Topic: Theme A: β-Amyloid Diseases / A04.h. Imaging, Biomarkers, Diagnostics: CSF- and blood-based biomarkers
Presenting Author: Hugo Vanderstichele, Bioanalytical Methods Consultant, Acumen Pharmaceuticals
Title: Development and Characterization of Novel Antibodies Targeting Amyloid Beta Oligomers with High Selectivity
Date/Time: Tuesday and Wednesday, March 17-18
Topic: Theme A: β-Amyloid Diseases / A02.b. Therapeutic Targets, Mechanisms for Treatment: Immunotherapy
Presenting Author: Erika Cline, PhD, Associate Director, Non-Clinical Development, Acumen Pharmaceuticals
Our oral presentation on Acumen’s research on EBD™ is part of an ongoing collaboration between Acumen and JCR Pharmaceuticals (JCR) announced in July 2025. This collaboration leverages Acumen's AβO-selective antibody expertise and JCR's transferrin-receptor-targeting technology, J-Brain Cargo®, with the goal of improving drug delivery to the brain and developing a more effective treatment option with an improved safety profile to slow or prevent neurodegeneration associated with AD. Our poster presentation is focused on NULISA SeqTm to establish a new analytical framework capable of detecting multiple low‑ and high‑abundance CNS biomarkers that sensitively reflect sabirnetug treatment effects. The results of this analysis provide a bioanalytical foundation for ongoing and future exploratory analyses using larger sample sets from the Phase 2 ALTITUDE‑AD study.
About Sabirnetug (ACU193)
Sabirnetug (ACU193) is a humanized monoclonal antibody (mAb) discovered and developed based on its selectivity for soluble amyloid beta oligomers (AβOs), which are a highly toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques. Soluble AβOs have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble AβOs, sabirnetug aims to address the hypothesis that soluble AβOs are an early and persistent underlying cause of the neurodegenerative process in Alzheimer’s disease (AD). Sabirnetug has been granted Fast Track designation for the treatment of early AD by the U.S. Food and Drug Administration and is currently being evaluated in a Phase 2 study in patients with early AD.
About ALTITUDE-AD (Phase 2)
Initiated in 2024, ALTITUDE-AD is a Phase 2, multi-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of sabirnetug (ACU193) infusions administered once every four weeks in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease. The study has enrolled 542 individuals with early Alzheimer’s disease (mild cognitive impairment or mild dementia due to AD) at multiple investigative sites located in the United States, Canada, the European Union and the United Kingdom. More information can be found on www.clinicaltrials.gov, NCT identifier NCT06335173.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
About the J-Brain Cargo® Platform Technology
JCR Pharmaceuticals has developed a proprietary blood-brain barrier (BBB)-penetrating technology, J-Brain Cargo®, to bring biotherapeutics into the central nervous system (CNS). The first drug developed based on this technology is IZCARGO™ (INN: pabinafusp alfa) and is approved in Japan for the treatment of a lysosomal storage disorder.
About JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd. is a global specialty pharmaceutical company that develops treatments that go beyond rare diseases to solve the world’s most complex healthcare challenges. JCR continues to build upon our 50-year legacy in Japan while expanding our global footprint into the US, Europe, and Latin America. JCR’s innovative therapies address conditions like growth disorder, MPS II, Fabry disease, acute graft-versus-host disease, and renal anemia. JCR is also developing treatments for rare diseases like MPS I, MPS II, MPS IIIA and B, and more. For more information, visit https://jcrpharm.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Any statement describing Acumen’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “believes,” “expects,” “anticipates,” “could,” “should,” “would,” “seeks,” “aims,” “plans,” “potential,” “will,” “milestone” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning Acumen’s business, the therapeutic potential of Acumen’s product candidate, sabirnetug (ACU193), and the potential to develop a candidate to treat Alzheimer's Disease utilizing EBD technology. These statements are based upon the current beliefs and expectations of Acumen management, and are subject to certain factors, risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing safe and effective human therapeutics. Such risks may be amplified by the impacts of geopolitical events and macroeconomic conditions, such as rising inflation and interest rates, supply disruptions and uncertainty of credit and financial markets. These and other risks concerning Acumen’s programs are described in additional detail in Acumen’s filings with the Securities and Exchange Commission (“SEC”), including in Acumen’s most recent Annual Report on Form 10-K, and in subsequent filings with the SEC. Copies of these and other documents are available from Acumen. Additional information will be made available in other filings that Acumen makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Acumen expressly disclaims any obligation to update or revise any forward-looking statement, except as otherwise required by law, whether, as a result of new information, future events or otherwise.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
ICR Healthcare
AcumenPR@icrhealthcare.com
FAQ
What will Acumen Pharmaceuticals (ABOS) present at AD/PD 2026 in Copenhagen?
When and what is Acumen's (ABOS) oral presentation at AD/PD 2026?
How do Acumen (ABOS) poster presentations at AD/PD 2026 relate to sabirnetug clinical work?
What collaboration does Acumen (ABOS) cite in its AD/PD 2026 presentations?
Will Acumen's (ABOS) AD/PD 2026 data affect the Phase 2 ALTITUDE‑AD study?
